Condition
PD-1 Inhibitors clinical trials and research
As of November 12, 2026, Find a Trial lists 4 PD-1 Inhibitors clinical trials that are recruiting, in China. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest PD-1 Inhibitors clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific | — | Beijing, Beijing Municipality | Recruiting | Jan 22, 2026 |
| Electro-Acupuncture plus PD-1 inhibitors and chemotherapy in advanced NSCLC | — | Guangzhou, Guangdong and 2 other locations | Recruiting | Jan 13, 2026 |
| Electroacupuncture plus PD‑1 immunotherapy for advanced non‑small cell lung cancer with ECOG 2 | — | Tianjin, Tianjin Municipality | Recruiting | Nov 20, 2025 |
| Electroacupuncture plus PD-1 immunotherapy for older adults with advanced non-small cell lung cancer | — | Tianjin, Tianjin Municipality | Recruiting | Jul 25, 2025 |
All recruiting trials (4)
-
Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific
This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.
-
Electro-Acupuncture plus PD-1 inhibitors and chemotherapy in advanced NSCLC
This trial tests whether adding electro-acupuncture to first-line PD-1 inhibitors plus chemotherapy helps people with advanced NSCLC who have no targetable mutations.
-
Electroacupuncture plus PD‑1 immunotherapy for advanced non‑small cell lung cancer with ECOG 2
This trial will see if adding electroacupuncture to PD‑1 immunotherapy helps people with advanced non‑small cell lung cancer who have an ECOG performance status of 2.
-
Electroacupuncture plus PD-1 immunotherapy for older adults with advanced non-small cell lung cancer
It will test whether adding electroacupuncture to PD‑1 immunotherapy helps people aged 65 and older with advanced non‑small cell lung cancer live longer, feel better, or have fewer side effects.
Related topics
Quick answers
How many PD-1 Inhibitors clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.